Skip to main content
Fig. 1 | Cancer Cell International

Fig. 1

From: Post treatment NLR is a predictor of response to immune checkpoint inhibitor therapy in patients with esophageal squamous cell carcinoma

Fig. 1

Association between response to anti-PD-1 treatment and NLR, PLR, MLR, SII at baseline, at 3 weeks post treatment and at 6 weeks post treatment. The patients were defined as high or low groups by NLR, PLR, MLR or SII level and then analyzed with Kaplan–Meier survival curves. a Progression-free survival (PFS) curves of patients with baseline low NLR and high NLR. b Progression-free survival (PFS) curves of patients with low NLR and high NLR at 3 weeks. c Progression-free survival (PFS) curves of patients with low NLR and high NLR at 6 weeks. d Progression-free survival (PFS) curves of patients with baseline low PLR and high PLR. e Progression-free survival (PFS) curves of patients with low PLR and high PLR at 3 weeks. f Progression-free survival (PFS) curves of patients with low PLR and high PLR at 6 weeks. g Progression-free survival (PFS) curves of patients with baseline low MLR and high MLR. h Progression-free survival (PFS) curves of patients with low MLR and high MLR at 3 weeks. i Progression-free survival (PFS) curves of patients with low MLR and high MLR at 6 weeks. j Progression-free survival (PFS) curves of patients with baseline low SII and high SII. k Progression-free survival (PFS) curves of patients with low SII and high SII at 3 weeks. l Progression-free survival (PFS) curves of patients with low SII and high SII at 6 weeks

Back to article page